SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK's long-acting injection beats Truvada in HIV prevention trial

05/18/2020 | 08:07am EDT
Outbreak of the coronavirus disease (COVID-19) in London

By Ludwig Burger

GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention.

The drug trial involving men who have sex with men was stopped early by an independent monitoring board after cabotegravir was found to be 69% more effective than the current standard of care, Truvada, the British drugmaker said on Monday.

But the market segment GSK is eyeing is about to become more competitive as cheaper generic versions of Truvada are expected to be launched in the United States in September, as the patent expires.

Gilead, for its part, hopes that Truvada users will opt against the cheaper copies and switch to its new daily pill Descovy, approved in October 2019 after it was shown to be less toxic to the kidneys and bones.

Truvada generated $2.8 billion (£2.31 billion) in sales last year, both from treatment and preventing an HIV infection.

Kimberly Smith, ViiV's head of research, said a long-acting injection was a better route of administer because users have shown to struggle with a strict routine of daily pills, heightening the infection risk.

"Individuals have to show up every eight weeks in the clinic for the injection but in-between there is not a need to take a pill daily, so you really change the equation for adherence with a long acting (drug)," Smith said.

GSK, which is trailing Gilead in the HIV treatment market, will speak to drug regulators about a possible approval of cabotegravir based on the prevention trial, a spokesman said.

Its shares were up 1.25% at 1120 GMT, outperforming a 0.8% gain in the STOXX Europe 600 Health Care

Prevention "has turned into a multi-billion opportunity for Gilead but we think consensus estimates include little or nothing for GSK in this market," UBS analysts said in a research note.

GSK has won approval in Canada for cabotegravir as one of two key ingredients in long-acting HIV treatment combination Cabenuva, whereas in the United States, the company has run into delays seeking the go-ahead for Cabenuva.

An initial readout from the trial, which started in late 2016, was previously not expected before next year.

A similar trial to test the cabotegravir injection to prevent HIV in women, is still ongoing.

Pfizer and Shionogi & Co Ltd hold small stakes in GSK's HIV-focused ViiV Healthcare division.

(Reporting by Ludwig Burger, editing by Louise Heavens)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 1.08% 64.35 Delayed Quote.-11.38%
GLAXOSMITHKLINE PLC 0.00% 1782 Delayed Quote.10.92%
PFIZER, INC. 1.00% 53.41 Delayed Quote.-9.55%
SHIONOGI & CO., LTD. -0.90% 6835 Delayed Quote.-14.25%
STOXX EUROPE 600 -1.14% 431.58 Delayed Quote.-10.51%
STOXX EUROPE 600 NR -1.14% 988.17 Delayed Quote.-9.02%
SWITCH, INC. 0.39% 33.5 Delayed Quote.16.52%
All news about GILEAD SCIENCES, INC.
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr..
05/19Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea..
05/18China Junshi's potential COVID drug shows promise in small trial
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
05/17WALL STREET STOCK EXCHANGE : Finding the tipping point
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 574 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 479 M - -
P/E ratio 2022 18,7x
Yield 2022 4,52%
Capitalization 80 715 M 80 715 M -
EV / Sales 2022 3,96x
EV / Sales 2023 3,84x
Nbr of Employees 14 400
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 64,35 $
Average target price 69,98 $
Spread / Average Target 8,75%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-11.38%79 850
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666
GENMAB A/S-18.02%20 276